Shanghai Genechem Co., Ltd. announced that it has received CNY 100,000,000 in a round of funding in January 2016. The transaction included participation from investors including HighLight Capital, China Renaissance Partners, Investment Arm, and returning investor Jiangsu Aoyang Health Industry Co.ltd. (SZSE:002172)
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
2.53 CNY | +0.40% |
|
0.00% | -33.25% |
1st Jan change | Capi. | |
---|---|---|
-33.25% | 27Cr | |
+3.94% | 305.77Cr | |
-2.01% | 119.03Cr | |
-41.64% | 102.92Cr | |
+18.94% | 95Cr | |
+7.72% | 83Cr | |
+9.60% | 81Cr | |
-29.75% | 69Cr | |
+39.95% | 54Cr | |
+17.81% | 54Cr |
- Stock Market
- Equities
- 002172 Stock
- News Jiangsu Aoyang Health Industry Co.ltd.
- Shanghai Genechem Co., Ltd. announced that it has received CNY 100 million in funding from HighLight Capital, China Renaissance Partners, Investment Arm, Jiangsu Aoyang Health Industry Co.ltd. and other investors